News | July 22, 2023
Lupin launches Luforbec 100/6 for adult asthma and COPD treatment in Germany
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
This transformation will enable GE HealthCare to build a strong foundation for business growth
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Cytel excels at using proven quantitative techniques to transform real-world data into actionable insights
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.
Subscribe To Our Newsletter & Stay Updated
